Back to search

Netherlands· NL-454abe882226

Grafalon 20 mg/ml concentraat voor oplossing voor infusie

A antithymocyte immunoglobulin (rabbit) product containing immunoglobuline, antithymocyten, registered in Netherlands by Neovii Biotech GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC L04AA04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedGrafalon 20 mg/ml concentraat voor op…ATCL04AA04REGISTER NO.NL-454abe882226PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Antithymocyte immunoglobulin (rabbit) is registered in 11 of 19 countries.

Countries holding a registration under ATC L04AA04 (antithymocyte immunoglobulin (rabbit)), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Antithymocyte immunoglobulin (rabbit) · ATC L04AA04

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
IMMUNOGLOBULINE, ANTITHYMOCYTEN
Manufacturer
Neovii Biotech GmbH
Country
Netherlands (NL)
ATC code
L04AA04
ATC class
Antithymocyte immunoglobulin (rabbit)
Defined daily dose
0.1 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    17602

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3a9779b6-3112-4f32-9bd3-265dcc02978e
GET /v1/drugs/3a9779b6-3112-4f32-9bd3-265dcc02978e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": null,
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h17602_smpc.pdf",
  "strength": null,
  "atc_label": "Antithymocyte Immunoglobulin (Rabbit)",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg17602",
  "excipients": [
    "FOSFORZUUR (E 338)",
    "NATRIUMDIWATERSTOFFOSFAAT 2-WATER (E 339)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "IMMUNOGLOBULINE, ANTITHYMOCYTEN"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h17602.pdf",
  "authorised_at": "1995/02/13",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "17602",
  "additional_monitoring": "N"
}

See everything about antithymocyte immunoglobulin (rabbit).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.